Hillsborough, NJ, United States of America

Bhaskara Rao Nallaganchu

This inventor holds 10 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Oncoceutics, Inc., Supernus Pharmaceuticals, Inc., Astrazeneca Ab. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bhaskara Rao Nallaganchu. Retrieved from https://idiyas.com/inventor/bhaskara-rao-nallaganchu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 6)

% Patents Active = 90.0

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 42(Granted Patents)

Company Filing History:

Supernus Pharmaceuticals, Inc.

Corridor Pharmaceuticals, Inc.

patent

Years Active: 2014-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12709602 - INTERMEDIATES FOR MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES (2026-08-18),

2. 12454535 - Substituted derivatives of isoindoles (2025-10-28),

3. 11976068 - 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy (2024-05-07),

4. 11964951 - Process of making derivatives of substituted morpholines (2024-04-23),

5. 10266533 - 7-Benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy (2019-04-23),

6. 9845324 - 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy (2017-12-19),

7. 9447122 - Arginase inhibitors and methods of use thereof (2016-09-20),

8. 9376437 - 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy (2016-06-28),

9. 9265765 - 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy (2016-02-23),

10. 8894970 - Arginase inhibitors and methods of use thereof (2014-11-25),

Title: Bhaskara Rao Nallaganchu: Innovator in Pharmaceutical Chemistry

Introduction

Bhaskara Rao Nallaganchu is a notable inventor based in Hillsborough, NJ, who has made significant contributions to the field of pharmaceutical chemistry. With a total of nine patents to his name, he has focused on developing innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Nallaganchu has developed substituted derivatives of isoindoles. These compounds, specifically 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol, along with their stereoisomers and pharmaceutically acceptable salts, are designed for use in pharmaceutical compositions aimed at treating central nervous system diseases or disorders. Additionally, he has worked on 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one and its analogs, which are intended for therapeutic use, including cancer treatment.

Career Highlights

Nallaganchu has had a distinguished career, working with prominent companies in the pharmaceutical industry. He has been associated with Oncoceutics, Inc. and Supernus Pharmaceuticals, Inc., where he has contributed to the development of innovative therapeutic solutions.

Collaborations

Throughout his career, Nallaganchu has collaborated with esteemed colleagues, including Gary Olson and Martin Stogniew. These partnerships have further enhanced his research and development efforts in the pharmaceutical sector.

Conclusion

Bhaskara Rao Nallaganchu is a prominent inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of various diseases. His innovative patents and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.